Evolving Treatment in Newly Diagnosed Multiple Myeloma Patients - Episode 7

Overview of PERSEUS, IsKia, and GMMG-HD7

Douglas Sborov, MD, discusses a brief overview of key clinical trials, including PERSEUS, IsKia, and GMMG-HD7, highlighting their implications for the treatment of patients with NDMM.

EP. 1: Key Considerations and Patient Factors in Frontline Therapy Selection for Transplant-Ineligible NDMM Patients
EP. 2: Brief Overview of MAIA, IMROZ, BENEFIT, and CEPHEUS Clinical Trials
EP. 3: Impact of Clinical Trials on the Treatment Landscape for TIE NDMM and Decision-Making Between Triplet vs Quadruplet Therapy
EP. 4: Optimizing Regimens and Managing Adverse Events in TIE NDMM
EP. 5: Looking Ahead and Key Takeaways
EP. 6: Current Treatment Landscape of Newly Diagnosed Multiple Myeloma Patients
Now Viewing
EP. 7: Overview of PERSEUS, IsKia, and GMMG-HD7
EP. 8: Clinical Factors for Transplant Eligibility and Treatment Strategy in NDMM
  1. Please provide a brief overview of the following trials:
  • PERSEUS
  • IsKia
  • GMMG-HD7

Related Content:

Evolving Treatment in Newly Diagnosed Multiple Myeloma Patients
Clinical Factors for Transplant Eligibility and Treatment Strategy in NDMM
Current Treatment Landscape of Newly Diagnosed Multiple Myeloma Patients
Looking Ahead and Key Takeaways